Ntla stock forecast.

Current. -$1.48. 1 Month Ago. -$1.60. 3 Months Ago. -$1.63. Intellia Therapeutics Inc. analyst estimates, including NTLA earnings per share estimates and analyst recommendations.

Ntla stock forecast. Things To Know About Ntla stock forecast.

NTLA Stock Dives As Competition Heats Intellia tested four doses of its one-time drug. The best response came from the highest dose, which led to a 93% average reduction in transthyretin protein.NTLA stock's Price/Earning ratio is 115.00. Our analysis grades NTLA stock's Price / Earning ratio at F. This means that NTLA stock's Price/Earning ratio is above 92% of the stocks in the Biotechnology sector in the NSD exchange. Based on this NTLA may be a overvalued for its sector.Find the latest Intellia Therapeutics, Inc. (NTLA) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo Finance٢٠‏/٠٧‏/٢٠٢٣ ... As of Thursday, July 20, Intellia Therapeutics Inc's NTLA share price has dipped by 5.13%, which has investors questioning if this is right ...The stock market has always been a volatile environment – but the last several weeks have seen an increase in that phenomenon. The bull market of 2021 shifted into reverse in January, and increased intraday swings, along with a partial reversal of losses, have been the order of the day in February. Unsurprisingly, much of the market’s …

While NTLA stock may have its naysayers, so far, Wall Street analysts strongly support it. Presently, analysts peg Intellia shares as a consensus strong buy. Also, their average price target ...

The current Intellia Therapeutics [ NTLA] share price is $28.76. The Score for NTLA is 45, which is 10% below its historic median score of 50, and infers higher risk than normal. NTLA is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.

On today's stock market, NTLA stock skidded 3.8%, reversing from a premarket climb and closing at 27.96. Shares of Regeneron Pharmaceuticals ( REGN ), which is collaborating with Intellia on the ...Intellia's Q1 2023 financial report shows a cash position of $1.2 billion, with collaboration revenue rising to $12.6 million and a net loss of $103.1 million. The success of NTLA-2002 in further ...(See NTLA stock forecast)Pacific Biosciences (PACB)We’ll stay in the biotech space for the next Wood-backed name, although Pacific Biosciences operates in a different segment.View Intellia Therapeutics, Inc NTLA investment & stock information. Get the latest Intellia Therapeutics, Inc NTLA detailed stock quotes, stock data, Real-Time ECN, charts, stats and...Predicting the weather has long been one of life’s great mysteries — at least for regular folks. Over the years, you’ve probably encountered a few older adults — maybe even your own grandparents — who made some weather predictions based on ...

Discover historical prices for NTLA stock on Yahoo Finance. View daily, weekly or monthly format back to when Intellia Therapeutics, Inc. stock was issued.

Real time Intellia Therapeutics (NTLA) stock price quote, stock graph, news & analysis.

Apr 18, 2023 · Analysts are bullish on NTLA stock. It currently has a mean price target of $97.19 which would be a gain of over 154% from the current price and institutional investors own approximately 85% of ... Shares of Intellia Therapeutics, Inc. (NTLA) have gained 23.5% over the past four weeks to close the last trading session at $43.19, but there could still be a solid upside left in the stock if ...Jul 27, 2023 · Read why NTLA stock is a Buy. Intellia is a pipeline-stage firm, leveraging gene-editing technology to develop therapies for rare diseases. ... So, I forecast NTLA’s cash flow statement using ... Analyst Forecast According to 21 analysts, the average rating for NTLA stock is "Buy." The 12-month stock price forecast is $77.4, which is an increase of 161.22% from the latest price.The stock price of Intellia Therapeutics (NASDAQ: NTLA), a biotechnology company developing treatments using a CRISPR gene-editing system, has seen a solid 15% rise over the last five trading days ...

Intellia’s recent data from its Regeneron collaboration for CRISPR-based NTLA-2001 shows a durable response to the lead in vivo genome editing candidate. ... The stock is set to report Q2 2022 ...Dec 1, 2023 · Intellia Therapeutics last announced its quarterly earnings results on November 9th, 2023. The reported ($1.38) earnings per share for the quarter, topping the consensus estimate of ($1.52) by $0.14. The business earned $11.99 million during the quarter, compared to the consensus estimate of $12.45 million. About the Roku, Inc. stock forecast. As of 2023 November 30, Thursday current price of ROKU stock is 106.720$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception).. Roku Inc - Class A stock price as been showing a rising tendency so we believe that similar market segments …That revenue goes along with positive earnings per share of $12.83 in 2022. And the forecast is that Vertex will grow earnings in 2023. ... Analysts are bullish on NTLA stock. It currently has a ...Find the latest Caribou Biosciences, Inc. (CRBU) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Performance Outlook. Short Term. 2W ...(See NTLA stock forecast)Pacific Biosciences (PACB)We’ll stay in the biotech space for the next Wood-backed name, although Pacific Biosciences operates in a different segment.Wall Street Stock Market & Finance report, prediction for the future: You'll find the Regeneron Pharmaceuticals share forecasts, stock quote and buy / sell signals below. According to present data Regeneron Pharmaceuticals's REGN shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists).

Intellia Therapeutics Inc’s ( NTLA) price is currently down 4.05% so far this month. During the month of April, Intellia Therapeutics Inc’s stock price has reached a high of $40.67 and a low of $34.41. Over the last year, Intellia Therapeutics Inc has hit prices as high as $76.45 and as low as $32.44. Year to date, Intellia Therapeutics Inc ...Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $1.41. This compares to loss of $1.96 per share a year ago.

Nov 30, 2023 · Analyst Forecast According to 21 analysts, the average rating for NTLA stock is "Buy." The 12-month stock price forecast is $77.4, which is an increase of 161.22% from the latest price. Intellia Therapeutics (NTLA 2.54%) works in the up-and-coming area of gene editing. Invitae ( NVTA -0.52% ) specializes in genetic testing. Both stocks have declined over the past year.Sep 6, 2023 · Intellia has declined in the double digits over the past year. Superstar investor Cathie Wood is increasing her bet on a cutting-edge technology that could transform the treatment of many diseases ... Intellia Therapeutics, Inc. CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing ...See Intellia Therapeutics, Inc. (NTLA) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.Find the latest Intellia Therapeutics, Inc. (NTLA) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo FinanceWhile many growth stocks have rallied in 2023, Exelixis stock has moved up and down since the start of the year. ... NTLA-2002 could be a game-changing treatment for hereditary angiodema (HAE), a ...Stock Price Forecast. The 24 analysts offering 12-month price forecasts for Intellia Therapeutics Inc have a median target of 72.00, with a high estimate of 145.00 and a low estimate of 29.00. The median estimate represents a +175.23% increase from the …The stock price of Intellia Therapeutics (NASDAQ: NTLA), a biotechnology company developing treatments using a CRISPR gene-editing system, has seen a solid 15% rise over the last five trading days ...Wall Street Stock Market & Finance report, prediction for the future: You'll find the Regeneron Pharmaceuticals share forecasts, stock quote and buy / sell signals below. According to present data Regeneron Pharmaceuticals's REGN shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists).

4 Growth Stocks, 4 Value Stocks to Buy Each stock offers a different opportunity in this uncertain market outlook. Jeff Reeves and Jordan Schultz Nov. 27, 2023

NTLA Stock 12 Months Forecast. Based on 19 Wall Street analysts offering 12 month price targets for Intellia Therapeutics in the last 3 months. The average price target is $78.65 with a high forecast of $136.00 and a low forecast of $31.00. The average price target represents a 151.68% change from the last price of $31.25. Find the latest Intellia Therapeutics, Inc. (NTLA) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo FinanceNov 29, 2023 · Complete Intellia Therapeutics Inc. stock information by Barron's. View real-time NTLA stock price and news, along with industry-best analysis. Find real-time CRSP - CRISPR Therapeutics AG stock quotes, company profile, news and forecasts from CNN Business. The Intellia Therapeutics Inc stock price gained 2.54% on the last trading day (Friday, 24th Nov 2023), rising from $30.26 to $31.03. During the last trading day the stock fluctuated 5.87% from a day low at $30.13 to a day high of $31.90. The price has risen in 6 of the last 10 days and is up by 24.32% over the past 2 weeks.Intellia Therapeutics Inc. analyst ratings, historical stock prices, earnings estimates & actuals. ... Stock Price Target NTLA. High $ 145.00: Median $ 72.00: Low $ 29.00: Average $ 76.00: Current ... Find the latest Intellia Therapeutics, Inc. NTLA analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range. investment rating.Being prepared to weather a hurricane — whether that involves fortifying your home or creating an emergency evacuation plan — is an important part of making it through the storm. Hurricanes travel across the ocean via massive, circular gust...Nov 24, 2023 · The Intellia Therapeutics Inc stock price gained 2.54% on the last trading day (Friday, 24th Nov 2023), rising from $30.26 to $31.03. During the last trading day the stock fluctuated 5.87% from a day low at $30.13 to a day high of $31.90. The price has risen in 6 of the last 10 days and is up by 24.32% over the past 2 weeks.

Stock Price Forecast The 24 analysts offering 12-month price forecasts for Intellia Therapeutics Inc have a median target of 72.00, with a high estimate of 145.00 and a low estimate of 29.00. Intellia Therapeutics Stock Chart and Share Price Forecast, Short-Term "NTLA" Stock Prediction for Next Days and Weeks Walletinvestor.com Intellia Therapeutics Inc (NTLA) Forecast Chart, Long-Term Predictions for Next Months and Year: 2023, 2024 The average TDOC stock price target stood at $124.77 a share, resulting in a potential 64% upside based on the last closing price of $75.86 (as of 28 February). The highest 12-month Teladoc share price forecast was $215, while the lowest was set at $67. Right after the company announced its results for the fourth quarter of the 2021 fiscal …Instagram:https://instagram. how does ninjatrader workwhy nvda stock is downbreeze long term disability insuranceonline bank account apps February 6, 2023 at 9:35 AM · 6 min read. The tech-heavy Nasdaq represents a collection of more risky stocks than the other major indexes and that is reflected by a poorer performance in bear ... merrill lynch solo 401kforex trading signal service The stock market has always been a volatile environment – but the last several weeks have seen an increase in that phenomenon. The bull market of 2021 shifted into reverse in January, and increased intraday swings, along with a partial reversal of losses, have been the order of the day in February. Unsurprisingly, much of the market’s … best schwab mutual funds 2023 Jun 23, 2023 · This stock has a credible chance of climbing, if not soaring. ... In the same period, the company plans to submit an IND for NTLA-3001, its therapy for alpha-1 antitrypsin deficiency-related lung ... About the Visa, Inc. stock forecast. As of 2023 December 02, Saturday current price of V stock is 256.450$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception).. Visa Inc - Class A stock price as been showing a rising tendency so we believe that similar market segments were very popular …